Completed NA INTERVENTIONAL 1-arm NCT01075802

Study of Tamoxifen Dose Escalation in Breast Cancer Patients With CYP2D6 Polymorphisms (TADE)

A Multi-Centre Study of Tamoxifen Dose Escalation Study in Breast Cancer Patients With CYP2D6 Polymorphisms

Sponsor: St George Hospital, Australia

Conditions Breast Cancer CYP2D6 Polymorphism

Interventions Tamoxifen

Updated 5 times since 2017 Last updated: May 3, 2013 Started: Mar 31, 2010 Primary completion: Oct 31, 2012 Completion: Dec 31, 2012

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT01075802, this NA trial focuses on Breast Cancer and CYP2D6 Polymorphism and remains completed. Sponsored by St George Hospital, Australia, it has been updated 5 times since 2010, reflecting limited change activity. This study contributes to the evolving evidence base for cancer treatment protocols.

Status Flow

Change History

5 versions recorded

Sep 2024 — Present [monthly]

Completed NA
Jul 2024 — Sep 2024 [monthly]

Completed NA
Jan 2021 — Jul 2024 [monthly]

Completed NA
Jun 2018 — Jan 2021 [monthly]

Completed NA
Jan 2017 — Jun 2018 [monthly]

Completed NA

First recorded

Mar 2010

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

St George Hospital, Australia
Western Sydney Local Health District

Data source: Western Sydney Local Health District

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Sydney, Australia
• Westmead, Australia